Revolution Medicines to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Revolution Medicines, Inc. CEO Mark A. Goldsmith, M.D., Ph.D. will be a featured speaker at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference and the TD Cowen 44th Annual Health Care Conference. The company's participation details, including dates, times, and locations, are provided in the press release. Live webcasts and replays of the presentations will be available on the Revolution Medicines website.

REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be a featured speaker at the Guggenheim Healthcare Talks 6^th Annual Biotechnology Conference and the TD Cowen 44^th Annual Health Care Conference.

Details of the company’s participation are as follows:

• Guggenheim Healthcare Talks 6^th Annual Biotechnology Conference
  Conference Dates: February 7-8, 2024
  Fireside Chat Time/Date: 3:00 p.m. Eastern on Wednesday, February 7, 2024
  Location: New York, NY; webcast available

• TD Cowen 44^th Annual Health Care Conference
  Conference Dates: March 4-6, 2024
  Fireside Chat Time/Date: 2:10 p.m. Eastern on Wednesday, March 6, 2024
  Location: Boston, MA; webcast available

To access the live webcasts of the presentations, please visit the “Events & Presentations” page of Revolution Medicines’ website at https://ir.revmed.com/events-and-presentations. Additionally, replays of the webcasts will be available on the “Events & Presentations” page of the Revolution Medicines website for at least 14 days following each conference.

About Revolution Medicines, Inc.
Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS companion inhibitors for use in combination treatment strategies. The company’s RAS(ON) inhibitors RMC-6236, a RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON) G12C-selective inhibitor, and RMC-9805, a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional RAS(ON) mutant-selective inhibitors in the company’s development pipeline include RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C).

FAQ

When is the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference?

The conference dates are February 7-8, 2024.

What time and date is the Fireside Chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference?

The Fireside Chat is at 3:00 p.m. Eastern on Wednesday, February 7, 2024.

Where is the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference located?

It is located in New York, NY; a webcast is available.

Where can I access the live webcasts of the presentations?

You can access the live webcasts on the 'Events & Presentations' page of Revolution Medicines' website.

For how long will the replays of the webcasts be available?

Replays will be available for at least 14 days following each conference on the 'Events & Presentations' page of the Revolution Medicines website.